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Chemsex, defined as the use of drugs before or during sex to enhance and facilitate the 
experience, is increasingly prevalent in urban populations of men who have sex with 
men. Chemsex is associated with higher risks of sexually transmitted infections including 
HIV, and it has negative effects on mental health and productivity. However, chemsex is 
under- or un-addressed in most primary care practices, and chemsex users rarely present 
to specialists in addiction medicine. We hypothesize that an integrative, multimodal 
training program for urban primary care providers in chemsex identification and harm 
reduction will increase the proportion of male patients screened for chemsex. We propose 
a stepped-wedge cluster randomized trial to measure baseline prevalence of screening 
and determine the effect of training on the relative risk of screening. Screening and 
appropriate safety counseling can stem the progression of the epidemic and reduce the 
burden of consequences associated with chemsex.   
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CHAPTER ONE - INTRODUCTION 
1.1 Background 
1.1.1 Chemsex Proliferation and Associated Risks 
Chemsex can be defined as the use of drugs before or during sexual experiences 
in order to facilitate or enhance the experience1. Typical substances identified in the 
literature associated with chemsex include crystal methamphetamine, gamma 
hydroxybutyric acid (GHB), gamma butyrolactone (GBL), and less frequently inhaled 
nitrates (“poppers”), phosphodiesterase-5 inhibitors (Viagra), and 3,4-Methylenedioxy
methamphetamine (“ecstasy”) 2. Chemsex is a distinct form of recreational drug use, with 
its own culture and language allowing users to communicate, source drugs, and plan 
meetings openly on apps and social platforms. For this reason some postulate that 
chemsex has been expanding in communities of men who have sex with men (MSM) in 
the age of gay social apps like Grindr and Scruff which enable these interactions3,4. 
Chemsex itself has several pseudonyms both in literature and online, and is commonly 
referred to as “sexualized drug use” or “party and play.”  
The 56 Dean St. Clinic in London, a premier sexual and gender minority health 
center specializing in chemsex research and treatment, define chemsex as being 
associated with prolonged sex, extreme sexual practices, multiple partners, disinhibition, 
unpredictable drug interactions, inexperienced injection use, poor condom use, poor 
antiretroviral adherence, frequent sexually transmitted infections (STI), and psychosis5. 
Regardless of the source of the definition there is general consensus that chemsex is 
associated with high risk sexual behavior and high rates of HIV and STI transmission1,2. 
In particular its associations with serodiscordant sex, condom-less sex, and group sex 
 2 
make chemsex of particular concern for HIV transmission, and it likely contributes to  the  
disproportionate burden of HIV transmissions affecting MSM6,7. The marathon nature of 
chemsex afforded by use of substances like methamphetamines is thought to facilitate 
transmission due to the ensuing rectal trauma of extended sessions and group sex 
activities, as well as the lack of pain or fatigue perception6. Additionally, the culture of 
early exposure of young gay males to chemsex online and associated inexperienced drug 
use contributes to sexual risk behavior and HIV seroconversion in young MSM5,8. 
1.1.2 Epidemiology of Chemsex 
Estimating the true prevalence of chemsex within both national and international 
MSM communities has proven difficult, and there is a great deal of heterogeneity in the 
literature in terms of subject recruitment, sample size, and estimations2. In general studies 
of MSM reporting to sexual health clinics or presenting to care with an STI estimated 
relatively high prevalence, though perhaps an overestimate of the characteristics of the 
whole community2. New landmark research comparing heterosexual, bisexual, and 
homosexual men and women has provided invaluable insight. Across all groups chemsex 
was prevalent, however it was significantly higher in homosexual men9. Specifically, 
homosexual and bisexual men had statistically significant higher rates of use of cocaine, 
methamphetamines, GHB/GBL, MDMA, Mephedrone, phosphodiesterase inhibitors, 




Table 1. Chemsex Prevalence A tabulation created by Lawn W, Aldridge A, Xia R, 
Winstock AR (2019) of the percent of participants that reported “Yes, I have had sex 
while on this drug in the last 12 months” stratified by self-reported sexuality.9 
 
Use of methamphetamine, GHB/GBL, and poppers represented the greatest 
difference between MSM and heterosexual men, and the researchers concluded both that 
chemsex was a significant problem in MSM and that targeted measures for this group 
were warranted9. Variation in use patterns differ by country, further complicating 
confluence in literature reviews. In the United States it is likely that crystal 
methamphetamine represents the drug contributing most to chemsex, however polydrug 
use is also reported to be common8,10.  
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1.1.3 Barriers and Opportunities in Treatment 
As a problem there are three dynamics to chemsex that make it difficult to 
address: chemsex users do not view themselves as addicts and often do not present to 
care in addiction medicine or psychiatry11-13; use is thought to be fed by minority stress 
and internalized homophobia meaning potential solutions require an intersectional 
approach14,15; and there are no pharmacologic treatments for addiction to 
methamphetamines or GHB/GBL10,16.  
There is no single answer in the literature to why chemsex users differ in self-
perception as compared to the prototypical patient seen in addiction care settings. It is 
suggested that chemsex users may be more likely to have steady employment and social 
support, making them less likely to have a pathological view of their substance use11. One 
way this dissonance can be explained is through the cultural concept of the “weekend 
warrior”, a homosexual man with a stable, potentially high paying job who only 
participates in chemsex activities on the weekends. Such men present to society as 
successful and in control, however the danger lies when chemsex use crosses over into 
the work week, an unpredictable event trending towards an unstable spiral. The 
stereotype of the “circuit queen,” as well as culturally defined space also prove useful in 
attempting to understand the variant perspective of chemsex users. The element of 
defined space is pertinent to consider in both describing chemsex ecosystems, and 
modeling interventions17. Specifically, it is important to note the relationship between 
chemsex and the typified “gay scene,” urban districts with high concentrations of gay 
men, nightlife, and sex venues: clubs, saunas, and cruise bars13. Regardless of the 
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syndemics at play, the cognitive dissonance between self-perception, experienced risk, 
and quality of life has been verified in the data. In a UK study, more than half of gay 
chemsex users reported feeling that their drug use had no negative impact on their life 
despite evidence that an increasing number experienced both social and sexual health 
consequences6. Additionally, even for those who do seek help, typical addiction medicine 
and psychiatry practitioners may be ill equipped to assist these patients as usage patterns 
are distinct from opiate users—the population of substance users receiving the most 
attention from practitioners at this juncture18. 
To the second dynamic, there are described societal pressures that have created 
the disparity in prevalence such that chemsex is most prevalent in MSM by wide 
margins9,19. The association between substance use and various psychosocial factors 
affecting MSM is well documented: these factors include minority stress, experienced 
discrimination, and internalized homophobia20-22. Social determinants of health have 
similar negative outcome associations for other marginalized identities, such as racial 
minorities23.  Therefore, having multiple identities and their related forms of 
discrimination increases the odds of having a substance use disorder—a claim supported 
by multivariate analyses 24.  
While no pharmaceutical interventions exist for methamphetamine or GHB/GBL 
addiction, harm reduction efforts as well as behavioral and community interventions exist 
and have been proven effective12,25,26. Pre-exposure prophylaxis (PrEP) has been proven 
to be an effective strategy to reduce the risk of HIV seroconversion in chemsex users27,28.  
Safety counseling in an environment free of discrimination has also been shown to be an 
effective and attractive option for people who participate in chemsex 18. 
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1.2 Statement of the problem  
As chemsex users rarely present to addiction specialists, and harm reduction in 
chemsex requires a holistic approach that addresses the syndemics of discrimination of 
and minority stress, it is a topic well suited to primary care. However, primary care 
providers lack the knowledge to screen and identify chemsex users, and provide 
appropriate safety counseling. This demonstrates a need to educate primary care 
providers, specifically those practicing in or near urban “gay centers,” in chemsex 
screening, identification, and intervention. However, no current research exists 
demonstrating the effect of an educational training program for practicing primary care 
providers on relevant outcomes such as rates of screening for chemsex behaviors in male 
patients. 
 
1.3 Goals and Objectives 
The goal of our study is to determine if an integrative, multimodal training 
program on screening for chemsex behaviors, identifying users, and providing safety 
counseling is an effective strategy to improve the rate of chemsex behavior screening in 
urban primary care clinics in New York City. We also aim to determine baseline chemsex 
screening prevalence in urban primary care practices. Utilizing a cohort stepped-wedge 
cluster randomized design, our primary objectives will be to: 
1. Form a statistical estimate of the baseline prevalence of chemsex screening in 
urban primary care clinics in New York City. 
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2. Determine if a multimodal training program has a significant effect on the 
relative risk of chemsex screening in male patients as compared to control 
periods. 
Our secondary objectives are to: 
1. Determine if the intervention increases the proportion of male patients who 
receive chemsex safety counseling. 
2. Determine if the intervention increases the proportion of male patients with a 
documented sexual history. 
 
1.4 Hypothesis 
There will be a statistically significant increase in the proportion of male patients 
receiving chemsex screening during the intervention periods by urban primary care 
providers who have completed an integrative, multimodal training program as compared 
to the control periods. 
 
1.5 Definitions 
Training Program: The integrative, multimodal training program is a continuing medical 
education style activity inclusive of print material, interactive online resources and case 
based learning activities, and an in-person didactic and patient role play session. 
Chemsex behaviors: Behaviors relating to the use of drugs before or during intercourse to 
enhance or facilitate the sexual experience. Enhancement through the elevation of 
pleasure sensations and/or duration of intercourse, and facilitation by anxiolysis and 
lowered inhibition.  
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Safety Counseling: Dialogue between patient and provider about harm reduction 
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CHAPTER TWO - LITERATURE REVIEW 
2.1 Introduction 
Review of the current literature demonstrates that there are no studies or reviews 
on educating primary care providers on chemsex nor the effects of interventions on rates 
of chemsex behavior screening or relevant patient outcomes. Chemsex itself is a novel 
topic with the majority of articles published after 2015. While we cannot present research 
on the association between provider education and chemsex screening rates, we can 
present research on key points that guide our study rationale, namely: 
1. Articles that describe a need in primary care for sexual and gender minority 
(SGM) health education. 
2. Descriptive articles on screening rates in men who have sex with men. 
3. Articles demonstrating that multimodal continuing medical education (CME) 
programs increase screening rates.  
The first two topics demonstrate the need and novelty of our proposed experiment, while 
the last informs our approach in developing an intervention and plan for analysis. 
 We utilized Ovid Medline and Scopus to conduct a comprehensive literature 
search in December of 2019. We placed no restrictions on date of publication or language 
due to the novelty of our topic and scarcity of articles. Article titles and abstracts were 
reviewed to determine relevance and significance. In Scopus, keywords and synonyms 
we used in our search included: chemsex, sexualiz(s)ed drug use, party and play, 
sexualized drug taking, sexualized drug abuse, substance linked sex, and screening. Our 
secondary search included the key terms: continuing medical education, graduate medical 
education, screening rates, screening, prevention, behavioral intervention, primary care, 
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men who have sex with men, and sexual and gender minorities. Terms were recombined 
in novel ways to broaden scope, and the search within feature was utilized to find articles 
relevant to our study. Reference lists of select publications were also reviewed for 
relevant studies. In Ovid Medline subject headings identified and utilized were: medical 
education and graduate medical education. Chemsex, prevention, and screening rates 
were utilized along with subject headings to refine the search. Articles included in our 
literature review proved relevant to one of three aforementioned foci, and can be 
categorized as reviews, descriptive studies, experimental studies, and educational studies. 
 In addition to our comprehensive literature review, we conducted a supplementary 
search on Scopus for the purpose of describing the protocol, benefits, and disadvantages 
of stepped-wedge cluster randomized trials as they are a relatively uncommon design.  
Search terms used included stepped-wedge cluster randomized trial in combination with 
sample size, advantages, disadvantages, and protocol.  
 
2.2 Review of Relevant Literature 
2.2.1 Primary Care and Sexual and Gender Minority Health  
 Eleven articles were identified that describe the current state of sexual and gender 
minority (SGM) health knowledge and competency in primary care settings. There were 
six cross sectional surveys, one review article, three descriptive articles, and one 
experimental pre-post design study. The majority of articles were published within the 
past five years, which is important as large public health campaigns targeting health 
disparities have begun within the past decade, necessitating recent data to describe 
current needs. Despite social progress, all eleven articles described a lack of SGM health 
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knowledge as well as deficits in provider competence and confidence in caring for these 
patients. This section details a foundational need to educate primary care providers in 
SGM health including chemsex, a topic considered novel to this subject area. 
 Three cross sectional survey studies assessed primary care provider SGM health 
knowledge in the context of describing barriers associated with PrEP prescribing. One 
study reported that providers who provided care to patients with HIV were more likely to 
have knowledge of PrEP and SGM health, suggesting a role for provider interest in SGM 
health competency1. Another study surveyed patients instead of providers, and found that 
providers likely needed training not just in SGM health content but in providing 
culturally sensitive care to MSM and other SGM2. The third study supported these 
findings, but of note, the study specifically targeted providers in North Carolina making it 
less generalizable to providers in the Northeastern United States3. In sum, all three 
studies concluded that the largest barrier to PrEP prescription was a lack of provider 
knowledge. 
 A cross sectional survey of primary care providers in 2019 found that while 78% 
of providers felt comfortable treating SGM patients, they had deficits in health 
knowledge, proper screening and clinical management, and culturally competency 
relating to SGM patients4.  Another study of SGM health knowledge in residents found 
similar deficits that were equivalent across residency years, demonstrating that these 
topics are often not covered in standard graduate medical training5.  
Multiple articles have detailed unique clinical considerations and the importance 
of targeted preventative health measures in MSM populations. Specifically, there is a 
described need for more provider education and organizational support6,  as well as a 
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need to improve preventative health screening rates and the sexual health care of MSM in 
primary care settings7. A cross sectional survey of MSM looking at primary care provider 
rates of recommended preventative services found that provider knowledge of sexual 
behaviors was key, and that educational efforts should be aimed at both providers and 
MSM to improve communication8. 
One cross sectional survey asked sexual health practitioners about their perceived 
needs for chemsex services, education on chemsex, and clinical management training. 
The researchers found that practitioners in surveyed clinics were aware of chemsex, and 
that there was a demand for more training regardless of the services the clinic currently 
offered9. This particular study was conducted in the United Kingdom, which limits its 
generalizability to the United States. However, the study supports that chemsex falls 
under the scope of general medicine and sexual health. A literature review investigating 
methods to address chemsex in MSM found that essential to getting patients to disclose 
chemsex behaviors was provider knowledge on chemsex and SGM health10. Additionally, 
the article purported the role of primary care providers who are able to open 
communication with patients about chemsex in connecting these MSM to services and 
offering safety counseling. This sentiment was echoed in an older descriptive article that 
argued the vital importance of the sexual history in managing the clinical care of patients 
who participate in chemsex11. 
2.2.2 Screening in Men Who Have Sex with Men 
 Ten articles were identified pertaining to sexual health and drug use screening in 
MSM in primary care settings. Five of the articles specifically looked at screening in HIV 
positive MSM, a sub-population that is better studied than HIV negative MSM. Overall 
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studies found a link between sexual risk behaviors and drug use, as well as a deficit in 
preventative sexual health screenings in MSM despite increased STI prevalence in this 
population.  
 A retrospective cohort analysis of HIV positive MSM in the Study to Understand 
the Natural History of HIV and AIDS (SUN) trial looked at the relationships between 
screening, STIs, and drug use in primary care. The researchers found that having an STI 
was associated with recreational drug use, especially polysubstance use and chemsex 
substance use12. The original prospective cohort of the SUN trial was HIV positive men 
seen in primary care in five US cities. The researchers concluded that in HIV primary 
care better screening and substance use management was needed12. A prospective survey 
and drug toxicology study in HIV positive inpatients found high prevalence of drug use 
and higher likelihood of drug-related admissions as compared to a HIV negative control 
group13. Additionally, in the study cohort chemsex substances including amphetamines, 
GHB/GBL, and ketamine were exclusively found in MSM with high prevalence, 
warranting formal screening and referral processes for HIV positive inpatients13. 
However, this study was conducted in the United Kingdom where providers practice 
within an integrated health system that has greater awareness of chemsex. Therefore, the 
generalizability may be limited, and there is a potential for bias. 
In a retrospective cohort study again looking at HIV positive MSM, researchers 
found a high prevalence of substance use, as well as co-occurring mood and anxiety 
disorders that were under-identified in primary care14. Another study in HIV positive men 
similarly reported a high prevalence of STIs and substance use including chemsex, 
supporting the need for improved screening and inclusion of chemsex into the standard 
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sexual history15. A retrospective cohort study with a large sample size of urban-residing 
HIV positive MSM seen in primary care found that over 50% of subjects had used 
substances within the past three months, including over 20% who used crystal 
methamphetamine, a chemsex substance16. This study however did not address frequency 
of use, which is relevant both for management purposes as well as future research. 
 A literature review examining drug and alcohol screening found that screening, 
treatment, and referrals for drug use were plausible and beneficial in primary care 
settings17. A cross sectional study of primary care providers found low rates of syphilis 
screening in MSM patients, and provider educational needs regarding STIs in MSM18. 
Specifically, researchers found women were more likely to receive screening and testing 
despite the fact that syphilis primarily affects MSM18. A cross sectional study of Black 
MSM in Washington DC found that rates of preventative screenings were lower in 
regular primary care centers than in community health centers19.  
 Two cross sectional studies assessed general STI screening in MSM. One study 
set in Massachusetts found that STI screening rates were low, there was a high 
prevalence of risky sexual behavior, and that MSM who identify as bisexual had an 
increased risk of not receiving appropriate screening 20. The other study looked at a larger 
set of data from the US overall and found that STI screening in MSM nearly met the 
Center for Disease Control and Prevention (CDC) goal of once annually, but with large 
gaps along key demographics and risk behaviors, warranting more targeted screening 
practices21. 
2.2.3 Continuing Medical Education Activities to Improve Screening Rates 
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 Nineteen articles evaluating the effects of educational interventions on 
preventative screening were identified. Interventions designed to improve screening 
varied between studies in terms of length, online versus in-person, interactive versus 
didactic, and knowledge assessment format. The success of interventions on improving 
preventative screening was wide ranging with some studies reporting no significant 
effect, and others large increases. The majority of articles assessed continuing medical 
education (CME) style activities. While there was great variability regarding study 
design, prevention topic, and activity, themes emerged guiding the creation of future 
interventions. 
 A literature review on educational interventions to improve rates of chlamydia 
screening compared the effectiveness of different educational intervention designs and 
reported a comprehensive meta-analysis. The authors found that singular activities such 
as distributing printed educational materials or holding a didactic CME activity produced 
only modest improvements, if any22. The most effective interventions were multimodal, 
using combinations of distributing printed materials for patients and providers, in-person 
provider outreach activities, digital reminders, and didactic CME activities22.  
Another literature review examining interventions to increase colorectal cancer 
screening in African Americans purported that interventions that addressed the 
populations’ self-risk perception and increased provider confidence provided the most 
promise23. The generalizability of that review to our study may be limited given its 
specificity in terms of population and screening. Similarly, another article described a 
non-randomized controlled study of a multimodal media and provider education 
campaign to increase colorectal cancer screening in Vietnamese Americans24. Given the 
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cultural specificity of the described interventions, the study’s results are unlikely to be 
generalizable to another culture and screening topic. 
One randomized controlled trial and one prospective cohort study specifically 
looked at the effect of stand-alone one hour CME activities on screening. Both found that 
a CME activity alone had no statistically significant effect on screening25,26. Neither trial 
included a true control group; the one-hour CME activities in both cases were compared 
to a more effective intervention: a patient mailer or a digital provider reminder. The aim 
of both studies was to increase colorectal cancer screening, which generally remains a 
difficult goal due to low patient acceptability and interest27. Despite these threats to study 
validity, taken in context with the evidence presented in the reviews, it is likely that a 
brief CME activity alone is not enough to change provider behaviors. 
Three randomized controlled trials utilized digital technology in their 
interventions. Digital interventions described in these trials included both standard CME 
style online-modules, as well as longitudinal case-based learning and practice question 
models. All three studies reported positive results; however, the study utilizing a standard 
CME module reported only a decreased slope of screening decline in the intervention 
group28. While the study concluded that it favorably influenced provider screening rates, 
the failure to show a statistically significant improvement from baseline screening rate 
supports the theme that stand alone CME activities have minimal effects on screening 
rates. The other digital intervention studies reported much more favorable results, with 
one study reporting improved knowledge outcomes compared to standard education29. 
The third study reported results demonstrating that a digital education intervention was 
not only equivalent in effect to in-person training in terms of knowledge gains, but lead to 
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a statistically significant practice change, in this case rate of guideline-directed 
pharmacotherapy prescription30. This practice change was in comparison to both the in-
person training and the no-intervention control group, supporting the utility of interactive 
online CME style activities in affecting screening rates. 
Six experimental studies with no control group comparisons reported favorable 
outcomes using various educational interventions. One study looked at pre and post self-
reported pharmacotherapy prescriptions rates after a brief educational intervention. The 
investigators found that the intervention had a positive effect on prescription rates3. 
Considering that the study had providers self-report the outcome and there was no control 
group, the study validity must be questioned. Additionally, in the post-intervention 
survey less providers responded, and it is likely that those who did had an interest in the 
study topic, which could have introduced selection bias into the results. Two studies 
examined the effect of education programs in combination with tools including screening 
forms. Both studies reported promising results in improving STI screening in MSM, 
demonstrating a benefit in including screening tools in educational interventions aimed at 
increasing preventative screening in MSM31,32. Another study examined the effect of a 
digital education intervention on LGBT health knowledge and provider confidence, and 
found the intervention produced a positive result33. A similar pre-post test study found 
that case-based CME improved provider LGBT health knowledge5. Without a control the 
generalizability of this study is limited; however, it adds to the library of studies using 
online interventions to target screening and knowledge goals in minority health 
disparities. Finally, another study with a robust pre-post experimental design analyzed the 
effect of skills-based CME on five different preventative screening topics. The 
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investigators stratified the data across different clinical settings (urgent care, primary 
care, women’s health) and found that across all settings the CME activities increased  the 
risk of screening34. The study included a large sample size, and reached statistical 
significance for all outcomes. However, the study’s biggest threat to validity is that it did 
not include a control. 
Three other non-randomized controlled trials examined the effect of CME and 
video learning on screening rates. The first study found that a systematic approach to 
developing a quality CME produced a significant increase in screening and referral rates 
six months post intervention35. While including a control and having longer follow-up 
periods produced quality data, this study is markedly older than any others included in 
our search, making its generalizability to contemporary medicine of concern. Another 
study investigating a CME activity for sleep problems found that the intervention was 
effective at both increasing screening and improving treatment rates36. While the study 
showed strong results between intervention and control on relevant outcomes, the study 
measured its outcomes via patient report. Patient report avoids bias from providers self-
reporting their own positive practices however, it is not as objective as chart review or 
other concrete measures that prevent the introduction of bias. It is worth noting that in a 
study comparing chart review to patient report in measuring preventative screening in 
resident physicians, patient report was accurate except in vaccination and smoking37. 
Given that these topics carry social stigma, it is likely that patient report is an accurate 
measure of screening except in cases where the topic is vulnerable to social desirability 
bias. The final non-randomized controlled study found that a video training on social 
determinants of health led to a statistically significant increase in screening of two out of 
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six measured social determinants of health38. One of the patient outcomes, free formula 
distribution, also reached statistical significance post intervention38. While the study did 
not reach statistical significance on all their outcomes, the results suggest educational 
videos can have a positive effect on screening rates. 
 
2.3 Review to Identify Possible Confounding Variables  
Six articles were identified related to identifying potential confounding variables 
for our proposed study. Three articles described characteristics of primary care providers 
with the potential for confounding. A cross sectional survey found that female sex, 
teaching hospital affiliation, urban location, and having a systematic approach to 
screening sexual behavior were associated with provider identification of MSM39. As 
ascertainment of sexual behavior is the first step in providing appropriate screening, it 
follows a homogenous sample with aligning characteristics could cause positive 
confounding. A literature review describing the best methods for providers to assess for 
chemsex found that provider communication skills were linked to patient disclosure10. A 
cross-sectional study found that 80% of surveyed providers were concerned that 
collecting sexual orientation and gender identity routinely would offend patients40. Thus 
communication skills and provider bias are also potential confounders. 
 A retrospective cohort study evaluated the effect of housing status on risk of 
sexual health screening in HIV positive MSM. The researchers found that homelessness, 
irrespective of time spent in care was associated with a decreased risk of preventative 
screening41. A cross sectional study of young adult gay men in New York City found that 
attending school and having insurance were positive factors related to seeing a primary 
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care provider42. Overall, SGM status was associated with less access to primary care, 
with fear of being outed and unknowledgeable providers described as specific concerns in 
this population42. Another cross sectional study linked disclosure of sexual orientation to 
rates of appropriate screening8. In sum, patient characteristics with the potential risk for 
confounding include housing status, socioeconomic status, healthcare access, fear of 
discrimination, and disclosure of orientation to providers. 
 
2.4 Review of Relevant Methodology 
2.4.1 Overview of Stepped-Wedge Cluster Randomized Trial Design 
Once a novel study design, stepped-wedge cluster randomized trials (SW-CRT) 
have grown in popularity in contemporary research due to their unique advantages. 
Because the SW-CRT was a new methodology to us, we decided to conduct a literature 
review on its use to be certain that it was the best approach for our study.  Therefore, we 
are including the result of this review in this chapter as opposed to the following chapter 
on methodology. In the latter, we “pick up on” the information gained from our literature 
review and specifically describe how we use the SW-CRT in our research design.   
In a published literature review of contemporary trials, the majority studied 
educational interventions aimed at evaluating the relationship between training and 
behavioral change43. A SW-CRT is unique in that in the course of the study, all clusters 
experience an initial control period followed by a transition to an intervention period at 
different stepped time points43. The control in the SW-CRT is made of the same cluster, 
but at an earlier time period. As the design allows for within cluster comparison, there is 
less variance in treatment effect44. A literature review of the advantages and 
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disadvantages of the SW-CRT reported that the design is best for pragmatic trials of 
interventions that are both likely to be beneficial and unlikely to cause harm, such as 
interventions aimed at promoting preventative screening45. Additional benefits of the 
design include that it reduces the need for stringent inclusion/exclusion criteria allowing 
for a better estimate of an intervention’s real world effect; it better accounts for temporal 
effects on an intervention; there is better differentiation of intervention effect from 
standard of care; and there are logistical benefits such as a smaller number of clusters 
required compared to parallel designs45,46.  
 As compared to standard parallel cluster randomized trials, the SW-CRT has 
unique limitations and considerations. Multiple studies have detailed that the design is 
more vulnerable to participant drop out and loss to follow up, making a priori suspicion 
of any adverse effects associated with an intervention a relative contraindication44,45.  
Depending on the length of each time period, measurement burden on participants and 
researchers is important to consider44. Additionally, blinding is not possible and there is a 
greater risk of contamination within the cluster data45. Given these considerations it is 
important to carefully evaluate the suitability of a SW-CRT over a parallel design based 
on study aims and characteristics of the proposed intervention. 
2.4.2 Sample Size in Stepped Wedge Cluster Randomized Trials 
 Multiple studies have documented the difficulties of sample size calculations in 
SW-CRT designs as well as a lack of proper reporting of sample size and analysis 
methodology43,46,47. When considering different approaches to the sample size 
calculation, it is likely that simulation-based methods are the most dynamic and 
utilitarian approach48. In simulation-based calculations of sample size it is necessary to 
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calculate a correction factor using parameters of the study design including number of 
cross over points, and number of measurement points per cross over49. In our study, we 
have opted to conduct a simulation-based calculation47,49-52. The parameters and 
methodology of our sample size calculation are described in detail in Chapter Three. 
2.4.3 Intervention and Outcome Variables 
 Section 2.2.3 describes in detail the literature on the designs of various 
educational training programs and their efficacy in improving knowledge scores and 
screening rates. Based on our comprehensive literature review, an integrated, multimodal 
educational intervention is likely to have the highest chance of success in improving rates 
of chemsex screening. Specifically, a multimodal intervention should include skills based 
exercises and role play34; use tools like screening forms31,32; include videos and online 
components28,30,38 ; and use email and chart reminders to increase provider 
participation53,54. In a literature review of sexual health screening in primary care, 
interventions that used monomodal educational interventions were found to be less 
effective at positively altering provider behavior22.  
The majority of studies included in section 2.2.3 measured outcomes in terms of 
proportion of patients screened before and after intervention. Methods to determine these 
proportions included provider report55, patient survey38, and chart review30. A study 
specifically comparing chart review against patient survey found that patients under-
reported screening for sensitive topics, in this case vaccination and smoking cessation37. 
Given the sensitivity of our subject, it is vulnerable to social desirability bias. As 
electronic record systems that support de-identified review are ubiquitous in large urban 
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health networks, chart review is likely the most appropriate and objective option for our 
study. 
Proportions in the studies in section 2.2.3 were compared before and after 
intervention using simple statistical tests like chi squared3 or Fishers exact test30. 
However, there is no validated absolute difference in screening rate that is clinically 
meaningful for our study population, setting, or screening topic in the literature. As it 
would be inappropriate to pick an arbitrary difference (e.g., change in proportion 
screened), and pre-determining a significant effect is important for the sample size 
simulation and ensuring proper study power, with guidance from a statistician 
experienced in SW-CRT, we decided to operationalize our data as a relative risk 
(RR=proportion screened during active intervention/proportion screened during control 
period). Specifically, we took guidance from a robust study analyzing the effect of 
interactive CMEs on five types of preventative screening in primary care to formulate our 
power calculation and variable operationalization34. This study was set in primary care, 
used a multimodal educational intervention, and looked at drug and sexual health 
preventative screening making it an appropriate model based on our study goal and 
objectives. The exact methodology of our power calculation and variable 
operationalization are described in detail in Chapter Three. 
 
2.5 Conclusion 
Overall, there is a body of evidence and expert opinion that confirms a lack of 
sexual and gender minority health knowledge in primary care, including MSM chemsex 
behaviors. There is also evidence that preventative screening rates in MSM populations 
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are low, and that provider education can have a positive impact on rates of preventative 
screening. Our study rationale then follows that an educational intervention aimed at 
primary care providers can improve the rate of chemsex behavior screening. A stepped 
wedge cluster randomized design is uniquely suited to this task as we are analyzing a 
novel topic and the design allows us to calculate a precise baseline prevalence in our 
study population, as well as get a better sense of our intervention’s real world effect. 
Furthermore, minimal exclusion criteria for providers are necessary for the design, and 
the direct comparison of the same group between control and intervention will allow for a 
better analysis of the intervention’s effect. Additional advantages of the design are 
described in section 2.4.1. While there are no biomedical interventions for chemsex56, 
screening represents the next step in an appropriately addressing this epidemic. 
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CHAPTER 3: METHODS 
3.1 Study Design 
This is a cohort stepped wedge cluster randomized control trial. Outcomes will be 
assessed by tabulating simple frequencies of study variables from review of regular 
patient charting and converting them into proportions of all male patients for analysis. In 
this study each clinic (k=18) will be a cluster, and clusters will be stratified by three 
geographic locations. Implicit bias and attitudes will be assessed upon enrollment and at 
the end of the twelve month study period to control for possible confounding using the 
Harvard Implicit Association test and the Gay Affirmative Practice Scale (Appendix A). 
A four month planning and recruitment period will precede phase one of the study. 
 
3.2 Study Population and Sampling 
Eighteen large primary care practices operating on electronic medical record 


















            = 1 Week Intervention
            = Control Period
            = Intervention Period
12 Month Stepped Wedge Study Design
Figure 1. Study Design A visual representation of the stepped 
wedge study design where each phase is 3 months of the study 
period, and each grouping of clinics contains 2 clinics from each 
borough: Manhattan, Brooklyn, and the Bronx. 
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willingness to participate. Large practices will be defined as practices with ten or more 
providers. Six clinics will be chosen from each of the three New York City boroughs 
included in our study: Manhattan, Brooklyn, and the Bronx. These boroughs were 
selected as they contain large healthcare conglomerates and “gay centers” or areas with 
concentrations of gay oriented nightlife. The study population will be participating health 
care providers at each of the study clinics. As patient-level outcome information collected 
from the study population will be anonymized and aggregated into counts screened – for 
example – among the total number of male patients seen during a study phase (every 3 
months) -  no informed consent from patients will be necessary. The intervention will be 
administered at the primary care provider level (physician associates, nurse practitioners, 
and physicians), among providers volunteering for the study in the eighteen participating 
primary care practices.  
Inclusion criteria for participants will include the following: (1) Hold an active 
medical license and be in good standing; (2) be employed full time at a participating 
primary care center located in Manhattan, Brooklyn, or the Bronx; (3) self-report 
providing direct patient care to an average of at least five patients per eight hour work 
period; (4) provide care to male patients. The purpose of these criteria are to ensure that 
outcomes are not diluted by care practitioners who serve part time in administrative roles, 
or who have minimal patient panels. Requiring active licensure and full time employment 
provides basic quality control, as all such participants must have completed an accredited 
health professional training program in order to achieve licensure. As the study 
intervention focuses on screening a subpopulation of male patients, a substantial portion 
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of a given provider’s patient panel must be male in order to measure the intervention’s 
effect.  
We will also collect provider-level information with regard to prior self-reported 
completion of a sexual and gender minority educational training program, such as a 
concentration course at a health professional school, LGBTQ+ health learning 
conference, or an online certificate program. This information will be used in the 
sensitivity analyses of the outcomes of interest, to examine whether in addition to the 
active intervention period, health care provider’s experience might also have a positive 
effect on screening. 
 
3.3 Subject Protection and Confidentiality 
Prior to the start of the study, all details and required documents will be submitted 
to the Yale University Institutional Review Board, including a waiver of all consent and 
waiver of privacy authorization. Our study falls under category five expedited review. 
Review of patient medical records will solely be to measure the number of male patients, 
tabulate frequencies of provider documentation of chemsex screening, sexual history 
taking, and chemsex safety counseling. No identifiable information will be collected on 
any patients, and chart review will utilize electronic medical record systems allowing for 
de-identified review. The study will meet criteria for waiver of consent as it poses 
minimal risk and does not affect the welfare or rights of the patient. Reviewers will be 
using redacted charts without name, age, address, or other identifying information, and 
will receive training to only review encounters for documentation of study variables. 
Reviewers will only record simple frequencies associated with a de-identified provider 
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number. Patients will not be subject to any special tests, harm, or alterations in standard 
care as the study is a provider level intervention. De-identification of patient charts, 
protection of protected health information, and reviewer training will meet the standards 
required for a waiver of authorization and HIPAA privacy requirements. 
         Informed consent will be obtained from all providers that agree to participate in 
this study (Appendix B). Participants will be assured that no identifying information will 
be collected, and that no data will be reported back to their employer. At the end of the 
study period all of each provider’s chart notes dated within the twelve month study period 
will be grouped and randomly assigned a number. Attitude surveys, and implicit 
associations tests will also be grouped with the assigned number. Investigators and chart 
reviewers will be blinded to the identity of the providers. After completion of the study 
and assignment of numbers to providers, no list of participants will be kept by the 
investigators, nor will any such list be published. Additionally, lists of participating 
providers will not be distributed to employers. 
         All hard copy consent forms will be stored in a secure, pass-coded location in a 
locked filing cabinet accessible only to the principal investigator. At the conclusion of the 
study all sensitive documents will be disposed of properly to ensure participant privacy 
and anonymity.  
 
3.4 Recruitment  
Providers will be recruited from the eighteen convenience selected large primary 
care practices in Manhattan, Brooklyn, and the Bronx. Generalist primary care practices 
with more than ten providers, inner city location, and electronic medical record systems 
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that support de-identified review will be contacted to participate in the study. Practices 
located in or near “gay districts,” defined as districts with a concentrated volume of gay 
nightlife venues, will be preferred. Providers will be voluntarily recruited by posters hung 
in staff work rooms, direct emails, and inclusion on employer communications like 
newsletters. Recruitment will be facilitated by collaboration with administrative leaders 
at participating practices. All providers interested in participating will be directed to take 
an online eligibility survey (Appendix C) to determine eligibility and provide contact 
information for further communications and acquisition of informed consent. 
Recruitment communications will not detail the subject matter of the intervention to 
prevent the introduction of bias. Communications will only state that providers must 
commit to a one week educational training at some time during the twelve month study 
period. Recruitment will take place over the four-month planning and recruitment period 
preceding the twelve-month, four-phase study period. 
 
3.5 Study Variables and Measures 
The independent variable will be completion of a multimodal training program. 
Chapter Two reviews in detail the literature supporting multimodal interventions. Our 
health care provider level intervention will include print materials and screening forms 
(Appendix D), online resources (Appendix E), interactive online content, and a three hour 
in-person training session including review of supportive materials, didactic 
presentations, and interactive case based and patient role play activities (Content 
Blueprint Appendix F). All parts of the intervention will be completed within one week. 
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The timing of the training intervention will vary between clinics based on their placement 
within the stepped wedge design.  
In our study, the exposure variable has two levels: (1) control period, where 
outcomes are observed under standard clinical practice, and (2) active intervention period 
where, once a practice is switched to receive intervention, volunteer health care providers 
will start participating in our training program and will then begin utilizing their acquired 
knowledge and skills in their practice.  
Our primary outcomes are (1) baseline prevalence of chemsex screening in urban 
primary care clinics in New York City, expressed as proportion of chemsex screening 
among the population of male patients seen at a clinic during the first phase of our study 
(first 3 months); and (2) change in the rate of chemsex screening in male patients 
between the control and active intervention periods. Our secondary outcomes are (1) 
change in the rate of chemsex safety counseling among male patients screened positive 
during chemsex screening between the control and active intervention periods; and (2) 
change in the proportion of male patients with a documented sexual history between the 
control and active intervention periods. 
Study variables will be measured by review of regular patient charting. We will 
use proportion of all male patients and not proportion of men who have sex with men to 
prevent possible confounding by differences in accuracy and rates of identification of 
men who have sex with men between the intervention and the control periods. 
 
3.6 Assignment of Intervention and Blinding 
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 Blinding of the intervention is not possible for researchers or the participants. Our 
study will use a stepped wedge design over a twelve month period (Figure 1). Clinics will 
be randomized into groups of six, made up of two clinics each from Manhattan, Brooklyn 
and the Bronx. Depending on which group their clinic is allocated to, participants will 




Completion of the in-person portion of the training program will be verified by 
sign in and sign out at the beginning and end of the training. Completion of pre and post 
tests for the online learning, and completion of responses to online patient cases will also 
be verified to assure providers in the intervention group completed the training program. 
 
3.8 Data Collection 
Data will be tabulated from deidentified electronic chart review at the end of the 
twelve month study period. All visit notes from participating providers will be collected 
from the start of the study period through the last day of the study period twelve months 
later. For each deidentified provider reviewers will tally the total number of male patients 
seen during each phase of the study period, as well as the total documented instances of 
chemsex screening, chemsex safety counseling, and sexual history taking in male patient 
chart notes. The data will be clustered by clinic, and stratified into groups by burrow 
location, and categorized by study period (intervention or control). Implicit Bias tests and 
attitude surveys collected at enrollment and at the completion of the study period will be 
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associated with the provider number for the purpose of bias and attitude analysis and 
controlling of possible confounding.  
 
3.9 Sample Size Calculation 
As described in Chapter Two SW-CRT are not common, and therefore, there is no 
standardized closed-form analytical formula for sample size. In order to obtain a sample 
size and ensure the study is adequately powered we propose the following approach: 
Using the literature to guide us in estimating baseline prevalence and setting our effect 
size, we will calculate a sample size estimate. After phase one of our study we will then 
conduct a precise simulation-based sample size and power calculation as discussed 
below, using the references from section 2.4.2.  
For the purpose of our preliminary sample size calculation we set an effect size of 
a 1.18 relative risk (RR=1.18) of screening, based on a study of the effects of interactive 
CME on multiple preventive screenings in the primary care setting that was most similar 
to our study in terms of intervention and aims1. Additionally, for the purposes of 
estimating baseline prevalence of screening (P2), we used a range of 0.05 (based on a 
study in a similar urban setting that found approximately 5% of patients are MSM2) to 
0.30 (the reported proportion of patients screened for drug use in a literature review of 
drug screening in primary care3). We set statistical power at 90%, and significance level 
at 5% (two-sided alpha=0.05). We then conducted a sensitivity analysis for the smallest 
detectable proportion of screened male patients during the active intervention period (P1). 
Figure 2 shows the range of detectable values for P1, varying the number of male patients 
seen in a clinic during the study (m: from 10 patients to 100 patients), varying the 
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measure of within-clinic correlation in the outcome across time (IntraClass Correlation, 
ICC: from 0.01 to 0.10), and using 18 clusters (k=18 clinics), with 6 clinics being 
switched from the control to active intervention period during 3 steps (see Figure 1). For 
example, in Figure 2f, if the baseline prevalence of screening is 30% (P2=0.30) and ICC 
is 0.08, a sample of 18 clusters in a complete stepped-wedge cluster-randomized design 
with 4 time periods (including the baseline), 3 steps, 6 clusters (clinics) switching from 
control to active treatment at each step, and an average of 40 subjects per cluster with an 
average of 10 subjects per cluster per time period (for a total sample size of N=720 
subjects) we will have 90% power to detect a difference between proportions of 0.06 
(RR=1.18). The test statistic used is the two-sided Wald Z-Test.  
We will revisit sample size at the end of the first phase in which all clusters will 
have finished the control period. At that time we will implement a series of simulations, 
using the same methods described above, to estimate a more precise sample size with 
adequate power to be able to detect the desired effect size of RR=1.18. Set variables in 
this simulation procedure will include the number of clusters (k=18 clinics) and time 
points (J= 4 three-month periods, meaning 3 steps or switches from control to active 
intervention), the average number of male patients seen in a clinic during phase I (m/4), 
and an estimated ICC and P2 from phase I. Our statistical power will remain at 90% and 
we will reject the null hypothesis of no difference in screening rate between the control 
























Figure 2a: Baseline Screening 
Prevalence, P2=0.05 
 
Figure 2b: Baseline Screening 
Prevalence, P2=0.10 
 
Figure 2c: Baseline Screening 
Prevalence, P2=0.15 
 
Figure 2d: Baseline Screening 
Prevalence, P2=0.20 
 
Figure 2e: Baseline Screening 
Prevalence, P2=0.25 
 




Figure 2. P1 Sensitivity Analysis Range of smallest detectable proportion of screened 
male patients during the active intervention period (P1) where set power is 0.90, 
significance level is 5% (two-sided alpha=0.05), m is the number of male patients seen in 
a clinic during the study, ICC is IntraClass Correlation in the outcome across time, k=18 
is the 18 clinics/clusters, and s=3 is the 3 steps at which 6 clinics are switched from 




Statistical analysis software will be used to analyze the collected data. 
Percentages will be calculated for each provider and data will be compiled and clustered 
by clinic, stratified by geographic region (Manhattan, Brooklyn, or the Bronx), and 
categorized by temporal study phase (intervention or control). A baseline prevalence of 
chemsex screening, expressed as a percent of all male patients with a confidence interval 
will be calculated using phase one data from the entire study sample, all eighteen clinics. 
We will use generalized linear mixed effects modeling (GLMM), to model 
g(E(Yilj=1|Xi,b0i, b0l)), which is the transformed probability (rate) of screening in a clinic i 
(i: 1…,k=18), for a health care provider (l:1,…,p), at time j (j:1,2,3,4 time periods), with 
the main effect of time period j (X2ij), and the time-varying covariate X1ij{1=Active 
intervention during a study phase, 0=Placebo during a study phase}. The actual models 
will be implemented on the aggregated counts of screens per clinic-per provider-per study 
phase, with an offset variable equal to the natural log of the number of male patients seen 
during a time period j in clinic i by health care provider l, and the link function g(.) for 
the mean response being ‘log’, so that we can obtain the estimate of relative risk (RR). 
We will incorporate a random intercept for each clinic (b0i) and each provider (b0l), which 
will allow us to estimate an ICC, in order to characterize the variability in the outcome of 
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interest across the different clinics (and across different providers). We will also conduct 
a per protocol analysis, including only data from providers who completed training.  
By exponentiating the estimated parameter for the effect of treatment (X1ij), we 
will obtain an estimated relative risk with surrounding 95% confidence intervals for the 
effect of the intervention on screening rate (i.e., proportion screened is actually the same 
as screening rate). Our secondary outcomes will be analyzed in similar fashion to the 
primary outcomes. 
Scores from the Harvard Implicit Association test and Gay Affirmative Practice 
scale will be aggregated and compared between clinics, and the three geographic regions 
(Manhattan, Brooklyn, and the Bronx) using linear mixed effects models (LME), which 
is similar to GLMM but the outcome of interest is a continuous variable, so the link 
function will be Identity. This variable will also be used in the sensitivity analysis for the 
primary outcome model, but including it as a health-care provider level covariate. 
 
3.11 Timeline and Resources  
The planning and recruitment period will commence January 1, 2021 and will 
finish on April 30, 2021. The study period will begin on May 3, 2021 and continue until 
May 2, 2022. Phase one will end July 31, 2021. Phase two will begin August 1, 2021 and 
end October 31, 2021. Phase three will begin November 1, 2021 and end January 30, 
2022. Phase four will begin January 31, 2022, and end May 3, 2022. The Intervention, 
including online learning, print materials distribution, and in-person sessions, will take 
place the first week of phases two through four for the assigned clinics. 
 41 
         The principle investigators will be John Encandela, PhD and Jona Tanguay, PA-
SII. The study will be based out of the Yale School of Medicine with support from the 
Dean’s Advisory Council on LGBTQI+ affairs and Veronika Shabanova, PhD from the 
department of Biostatistics. In-person training modules will be facilitated by Jona 
Tanguay, and participating practices will need to provide a classroom or break room for 
the training. A portable projector setup will be required for the in-person training 
sessions. A Yale Qualtrics account will be used to issue the eligibility survey, attitude 
surveys, as well as pre and post tests for the online content. An Information Technology 
professional will be needed to help translate the online learning content into an 
interactive format. The study will also require two research assistants to serve as chart 
reviewers, assist with data entry and analysis, and assist with communication with 
participating primary practice sites. Office space within the School of Medicine or Public 
Health will be required for the research assistants and principal investigators. 
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CHAPTER FOUR: CONCLUSION 
4.1 Advantages and Disadvantages  
A strength of our proposed study is the novelty of its topic and design. Chemsex 
is a relatively well described problem, yet there is a large gap in medical literature 
relating to interventions to address the epidemic in everyday clinical care. While 
community efforts have value and efficacy as described in Chapters One and Two, there 
is a need in healthcare for chemsex education so that MSM can access the care, testing, 
and safety information they need. The design of our study, a SW-CRT, is also uncommon 
though not novel in terms of published literature. Design specific advantages are 
described in section 2.4.1. A number of studies have validated the use of the stepped 
wedge cluster randomized design for low-risk educational interventions aimed at 
preventative screening and behavioral change1,2. Considering our proposed goal and 
objectives, the design is thus well suited.  
 The complicated analysis inherent in the SW-CRT is considered by some to be a 
limitation1. However contemporary guidance aiming to simplify the analysis have laid 
out effective frameworks3. A further step to our analysis might have been to obtain clinic-
level screening rates across study phases for all health care providers (not just those who 
were consented for this study) at each clinic to assess whether training a few providers 
can have a disseminating effect on clinics as a whole. However, this would have added an 
additional layer to the study that might go beyond the resources and time allotted, which 
are extensive. Should the study be expanded in the future or subsequent studies follow 
our framework, this aspect could be included.  
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Our design is superior to the many pre-post studies described in section 2.2.3 in 
that it has a control. As each cluster is its own control, the design is advantageous over 
parallel designs where such a precise level of control matching is unattainable. 
Additionally, our study protocol allows us to calculate an exact baseline prevalence 
across all clusters. However, our study like other SW-CRT is more vulnerable to being 
underpowered or failing to reach sample size4. To minimize this issue we employed a 
complex simulation procedure as described in Chapters Two and Three. Should the study 
fail to reach proper power after phase one the design is flexible and the study could either 
be conducted as a pilot or phase one could be extended and recruitment reopened. 
 The setting of our study is very specific, utilizing primary care centers only in 
three boroughs of New York City. While this a logical choice given the association of 
chemsex with “gay districts,” which was discussed further in Chapter One, it risks 
sacrificing generalizability for the sake of utility. Our study focuses on districts that are 
likely to have a high concentration of men who have sex with men, especially MSM who 
might attend gay night life venues and participate in chemsex based simply on 
geographic availability. It follows then that the results of this study would be 
generalizable to other American cities with known “gay districts” and “gay scenes” such 
as San Francisco, Chicago, Boston, Washington DC, and Los Angeles. This gives our 
study utility to guide primary care practices in urban locations. However, at the same 
time it makes the generalizability of the study to suburban and rural areas low given the 
differences in culture, population density, and primary care provision. Furthermore, 
studies have described lower levels of sexual and gender minority (SGM) health 
knowledge and competence in primary care providers in the Southern United States5. 
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Baseline differences in provider knowledge of chemsex and drug use in SGM populations 
may thus be an additional barrier to the generalizability of this study to other regions of 
the United States. It is also likely our study may be limited in its generalizability to other 
countries due to structural differences in health systems. However, as this will be the first 
study to focus on primary care providers and chemsex prevention, the study may serve as 
a model for others to expand upon in other systems and geographies. 
 Our study focuses specifically on men who have sex with men as studies have 
demonstrated chemsex is more prevalent in this population in comparison to heterosexual 
men and women6. However, heterosexual people still can and do participate in chemsex6. 
Transgender individuals are left out of the literature entirely, even though the prevalence 
of chemsex and related harms are likely similar or higher in transgender females as 
compared to MSM7. Though we do not include these populations in our study, future 
research may be indicated to better describe chemsex in these populations and determine 
appropriate interventions.  Our study design might be instructive for these future studies. 
 
4.2 Public Health Significance  
 There is a wealth of literature that describes health disparities affecting sexual and 
gender minorities. In research and in public health campaigns the focus primarily has 
been on addressing HIV in MSM. Substance use and substance use disorders are 
disproportionately prevalent in MSM and other sexual and gender minorities. Chemsex is 
a form of substance use distinct from the alcohol and opioid use disorders that primary 
care providers are trained in handling. Primary care providers, especially those in urban 
areas,  are uniquely positioned to make a difference in this epidemic as they are the ones 
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who communicate and build therapeutic alliances with these patients in everyday 
practice. However in order to make a difference, providers need to know about these 
behaviors and have the information and competence to intervene. Should our study 
produce positive results, it would make a case for standardizing chemsex screening in 
urban primary care. Additionally, if effective our training program could  be offered to 
primary care practices across all major American metropolitan areas. Increasing 
appropriate primary care intervention could substantially improve the disproportionate 
burden of chemsex on MSM communities and improve their productivity. Given the 
associations between chemsex and STIs/HIV, our intervention also has the potential to 
reduce the incidence and prevalence of these diseases in MSM which has positive 
ramifications for people of all sexual and gender identities. 
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B. Informed Consent Form 
COMPOUND AUTHORIZATION AND CONSENT FOR PARTICIPATION IN A 
RESEARCH STUDY 
 
YALE UNIVERSITY SCHOOL OF MEDICINE 
 
 
Study Title: Deidentified Provider Study 
Principal Investigator (the person who is responsible for this research): Jona 
Tanguay, PA-S (Jona.tanguay@yale.edu) 
Phone Number: 203-510-0005 
 
Research Study Summary: 
• We are asking you to join a research study. 
• The purpose of this research study is to determine the effect of a multimodal 
continuing medical educational program on select patient outcomes 
• Study procedures will include: participation in training program that will require no 
more than 10 hours of your time, including 3 hours of in person attendance. 
• The study may have no benefits to you. The study may benefit your patients, and 
improve some select patient outcomes. 
• Taking part in this study is your choice. You can choose to take part, or you can 
choose not to take part in this study. You can also change your mind at any time.  
Whatever choice you make, you will not give up any legal rights or benefits.  
• If you are interested in learning more about the study, please continue reading, or 
have someone read to you the rest of this document. Take as much time as you 
need before you make your decision. Ask the study staff questions about anything 
you do not understand. Once you understand the study, we will ask you if you wish 
to participate; if so, you will have to sign this form. 
 
 
Why is this study being offered to me? 
We are asking you to take part in a research study because you are a practicing primary 
care provider in Manhattan, Brooklyn, or the Bronx in one of the participating primary 
care centers. 
 
Who is paying for the study? 
Yale University School of Medicine 
 
What is the study about?  
The effect of a multimodal continuing medical education training program on select 
patient outcomes. 
 
What are you asking me to do and how long will it take?  
If you agree to take part in this study, this is what will happen: you will be randomly 
assigned to a group and you will be asked to complete an educational training program 
during one week of August 2021, November 2021, or February 2022. This will include an 
in person training session that is 3 hours long, as well as self-study online modules, 
quizzes, videos, and resources. The program should take no longer than 10 hours of 
your time total, and is confined to one week. You will also be asked to take surveys and 
implicit association tests at the beginning and end of the study period. During the study 
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period of May 3rd 2021 to May 3rd 2022 data will be collected from your patient charts 
using de-identified review. 
 
What are the risks and discomforts of participating?  
The study will pose no risks to your patients or to your employment. Your identity and 
participation will be kept confidential. The trainings contain sensitive topics, and you may 
experience mild discomfort. The trainings do not contain obscenity, or offensive content. 
The trainings do not advocate for any off label uses of drugs, or practices outside of 
standard medical procedure. 
 
How will I know about new risks or important information about the study?  
We will tell you if we learn any new information that could change your mind about taking 
part in this study.  
 
How can the study possibly benefit me? 
The study may provide you with useful tips for your practices that will help you better 
meet the needs of your patients. 
 
How can the study possibly benefit other people? 
This study may improve our understanding of how to address public health issues at the 
level of primary care. It may also benefit your patients If it improves the care they 
receive. 
 
Are there any costs to participation?  
If you take part in this study, you will not have to pay for any services, supplies, study 
materials or procedures. You will not be required to miss any work time, however during 
the week of the educational activities you will be asked to stay beyond the hours of your 
normal work week. You may also have to pay for additional transportation costs if the 
activities take place on days you are not scheduled to work. 
 
Will I be paid for participation?  
There will be no compensation for participating in this study. 
 
How will you keep my data safe and private? 
We will keep information we collect about you confidential. We will share it with others if 
you agree to it or when we have to do it because U.S. or State law requires it. For 
example, we will tell somebody if we learn that you are hurting a child or an older 
person. At the end of the study all identifiable data will be erased and data will be coded 
with numbers. We will not publish a list of participants or inform your employer about 
your participation in this study. During the study any identifiable information will be kept 
in a locked cabinet in a secure location. All electronic data will be properly encrypted and 
password protected.  When we publish the results of the research or talk about it in 
conferences, we will not use your name. If we want to use your name, we would ask you 
for your permission.  We will also share information about you with other researchers for 
future research but we will not use your name or other identifiers. We will not ask you for 
any additional permission. We will not distribute any identifiable information or contact 
information for use in future studies. 
 
What Information Will You Collect About Me in this Study? 
We will only collect the minimum necessary information about you for this study. This 
includes basic demographic information on an eligibility survey including questions about 
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your healthcare training, what kind of role you have in your workplace, and characteristics 
of your patient panel. Additionally, we will collect surveys and implicit association tests 
from you twice during this study. Data will also be collected about your clinical practices 
via de-identified chart review. All of this information will be assigned to a randomized 
number, so that none of the data we collect after the study begins will be associated with 
your name or any identifiable markers. 
 
How will you use and share my information? 
We will use your information to conduct the study described in this consent form.  
We may share your information with: 
• The U.S. Department of Health and Human Services (DHHS) agencies 
• Representatives from Yale University, the Yale Human Research Protection 
Program and the Institutional Review Board (the committee that reviews, approves, 
and monitors research on human participants), who are responsible for ensuring 
research compliance.  These individuals are required to keep all information 
confidential.  
• The study sponsor 
• Governmental agencies to whom certain diseases (reportable diseases) must be 
reported 
• Co-Investigators and other investigators  
• Study Coordinator and Members of the Research Team  
• Data and Safety Monitoring Boards and others authorized to monitor the conduct of 
the Study  
 
We will do our best to make sure your information stays private. But, if we share 
information with people who do not have to follow the Privacy Rule, your information will 
no longer be protected by the Privacy Rule. Let us know if you have questions about this. 
However, to better protect your health information, agreements are in place with these 
individuals and/or companies that require that they keep your information confidential. 
 
Why must I sign this document? 
By signing this form, you will allow researchers to use and disclose your information 
described above for this research study. This is to ensure that the information related to 
this research is available to all parties who may need it for research purposes. 
 
What if I change my mind? 
You may withdraw or take away your permission at any time. You may withdraw your 
permission by telling the study staff or by writing to Jona Tanguay, PA-S, 100 Church 
St. South at the Yale University, New Haven, CT 06520. 
 
If you withdraw your permission, you will not be able to stay in this study. No new 
information identifying you will be gathered after the date you withdraw. Information that 
has already been collected may still be used and given to others until the end of the 
research study to ensure the integrity of the study and/or study oversight.   
 
What if I want to refuse or end participation before the study is over?  
Taking part in this study is your choice. You can choose to take part, or you can choose 
not to take part in this study.  You also can change your mind at any time.  Whatever 
choice you make, you will not give up any legal rights or benefits.  
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Not participating or withdrawing later will not harm your relationship with your employer 
or with this institution.   
 
To withdraw from the study, you can call a member of the research team at any time and 
tell them that you no longer want to take part.  The researchers may withdraw you from 
participating in the research if necessary.  
 
What will happen with my data if I stop participating? 
As stated data collected in this study will be de-identified, meaning that it will not be 
possible to retrieve your data if you decide to no longer participate. 
 
Who should I contact if I have questions?  
Please feel free to ask about anything you don't understand.  
 
If you have questions later or if you have a research-related problem, you can call the 
Principal Investigator at 203-510-0005. 
 
If you have questions about your rights as a research participant, or you have complaints 
about this research, you call the Yale Institutional Review Boards at (203) 785-4688 or 
email hrpp@yale.edu. 
 
Authorization and Permission 
 
Your signature below indicates that you have read this consent document and that you 
agree to be in this study.   
 
We will give you a copy of this form. 
 
 
Participant Printed Name  Participant Signature  Date 
Person Obtaining Consent Printed 
Name 




Appendix C. Provider Eligibility Survey 
 
1. Please choose you practice from the drop down menu…  
 
2. Do you hold a valid medical license in your state of residence? 
 a. Yes 
 b. No 
 
3. Please select your medical qualification. 
 a. MD/DO 
 b. APRN 
 c. PA-C 
 
4. Are you currently being investigated by your supervising body? Is your license 
currently suspended? Have you ever been reprimanded or had your practice abilities 
revoked by your state medical board? 
 a. Yes 
 b. No 
 
4. Are you a full time clinician in a primary care practice (defined as providing patient 
care ~40 hours per week)? 
 a. Yes 
 b. No 
 
6. Do you spend part of your job time in an administrative role? 
 a. Yes 
 b. No 
 
7. Do you provide direct patient care to at least five patients every regular work period (8 
hours)? 
 a. Yes 
 b. No 
 
8. Do you provide primary care to male patients? 
 a. Yes 
 b. No 
 
9. Have you ever completed training in sexual and gender minority or LGBTQ+ health 
such as a medical school course, an online learning program, or a learning conference? 
 a. Yes 
 b. No 
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Ident ifying ChemSex in a  
clinical set t ing (GUM) - 
screening guidelines/alerts 
	
“Have you used drugs before/during sex in the last 6 months?”  
·         “ If yes,  Which? -  Mephedrone/GBL/Crystal Methamphetamine?”  
(i.e; emphasis on the recreational drugs that are associated with greater sexual 
disinhibition/sexual risk-taking). 
·         “ If yes - Did you inject?”  
(To highlight those needing needles/ injecting advice, and to alert non-sexually 
transmitted infection risks). 
·         Finally a question that could trigger a call to action/reflection  
(Examples; ‘Are you happy with your level of drug use?’, ‘When did you last have 
sober sex?” , “ do you feel your drug use is negatively impacting your sex life or 
general wellbeing?”  
  
Clinicians are encouraged to be particularly alert to the following risks; 
 
· High number of sexual partners per ChemSex episode  
· High frequency of ChemSex episodes  
· Long gaps between GUM/HIV screens/poor engagement with 
GUM/HIV/HCV appointments 
· Consistently poor condom use when using Chems 
· High number of STIs in last 6 months/multiple reinfections of HCV 
· High frequency of PEP presentations (if HIV-ve) 
· Seroconversion symptoms, that might be disguised as a drug ‘high’ or a 
drug ‘comedown’ 
· HIV+ve but not on treatment 
· Consistently poor antiretroviral adherence if HIV+ve (enough to 
increase infectiousness/ jeopardize viral suppression) 
· Dependent GBL use (daily, beyond 7 consecutive days) which can be 







How frequently have you used recreational drugs in the last 6 months? (Please circle)                            
 
Once Once a month 
or less 
A few times a 
month 






How strongly do you agree/disagree with the following statements: (please circle) 
 




Agree Neither agree nor 
disagree 
Disagree Strongly disagree 
 
 




Agree Neither agree nor 
disagree 
Disagree Strongly disagree 
 
 




Agree Neither agree nor 
disagree 
Disagree Strongly disagree 
 
 




Agree Neither agree nor 
disagree 
Disagree Strongly disagree 
 
 




Agree Neither agree 
nor disagree 
Disagree Strongly disagree Does not 
apply to me 
 
 









apply to me 
 
 
I am able to enjoy sex without using drugs 
 
Strongly agree Agree Neither agree nor 
disagree 
Disagree Strongly disagree 
 
 
If you wanted advice about your drug use, where would you prefer to get this?(Please Tick)    
 My GP practice 
 A standard drug service 
 A specialist gay/lesbian/bisexual/trans* counselling service?  
 A Sexual Health Clinic  
 Somewhere else (Tell us where) ________________________ 
 
 
Thank you. Now put this questionnaire in the box on the reception desk, or hand to a member of staff. 
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E. Chemsex Online Resource Guide 
 
▪ 56 Dean St London Clinic: https://dean.st/for-professionals/ 
o Provider tools and resources including: 
▪ Informational videos on chemsex, risk assessment, and harm 
reduction 
▪ Care plans 
▪ Motivational Support tools 
▪ Chemsex first aid information 
▪ Patient Information 
▪ Print-outs for Patients 
▪ National LGBT Health Education: https://www.lgbthealtheducation.org/#learn 
o Educational CME 
o Videos 
o Webinars 
o Conference Talks 
▪ GGD Amsterdam: https://www.ggd.amsterdam.nl/english 
o Information on chemsex, STIs, and MSM health concerns 
o Descriptions of specialized MSM services and chemsex services 
▪ Engage Montreal, CA: https://www.engage-men.ca/ 
o Relevant literature 
o Oral presentations and slide show presentation on chemsex 
▪ Resource pages and sample services 
 
F. Didactic Session Content Blue Print 
 
▪ Chemsex Content Review 
o Epidemiology 
o Contextualization, partner finding, and significance of culturally defined 
spaces and roles 
o Review of chemsex substances and their effects 
o Review of appropriate harm reduction interventions and principles of 
harm reduction and safety counseling 
▪ Chemsex Screening 
o How to utilize the sexual history and screening tools 
o Review of colloquial chemsex language 
o Creating a safe space, neutralizing stigma, and initiating patient centered 
safety discussions 
▪ Resource Review 
o Review of supplementary online resources as well as required interactive 
online curriculum to be completed 
▪ Interactive Learning 
o Patient-provider discussion role plays 
o Patient case based problem solving 
o Systems level creative problem solving cases 
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